| Angioedemas, Hereditary
Sajazir vs Haegarda
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Sajazir vs Haegarda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHaegarda has a higher rate of injection site reactions vs Sajazir based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Haegarda but not Sajazir, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sajazir
Haegarda
At A Glance
SC injection
As needed
Bradykinin B2 receptor antagonist
SC injection
Twice weekly
C1-esterase inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 30 mg SC injection in the abdominal area; additional doses at intervals of at least 6 hours if response is inadequate or symptoms recur; no more than 3 doses in 24 hours.
Angioedemas, Hereditary 60 IU/kg by subcutaneous injection twice weekly (every 3 or 4 days); self- or caregiver-administered after reconstitution.
Contraindications
—
- Life-threatening hypersensitivity reactions, including anaphylaxis, to C1-INH preparations or any excipient
Adverse Reactions
Most common (>1%) Injection site reactions, pyrexia, transaminase increased, dizziness
Postmarketing Urticaria
Most common (>4%) injection site reactions, hypersensitivity, nasopharyngitis, dizziness
Pharmacology
Icatibant is a competitive antagonist selective for the bradykinin B2 receptor; by blocking bradykinin binding to the B2 receptor, it treats the localized swelling, inflammation, and pain of acute HAE attacks caused by C1-esterase-inhibitor deficiency-driven excess bradykinin production.
C1-esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) that inactivates key proteases in the complement, fibrinolytic, and coagulation systems -- including C1r, C1s, factor XIIa, and plasma kallikrein -- thereby preventing bradykinin generation and reducing vascular permeability; HAEGARDA replaces the missing or malfunctioning C1-INH protein in HAE patients.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sajazir
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Haegarda
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Sajazir
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Haegarda
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Sajazir
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Haegarda
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SajazirView full Sajazir profile
HaegardaView full Haegarda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.